OriGene to add antibody expertise with $16M SDIX deal

04/9/2013 | GenomeWeb Daily News (free registration)

SDIX will sell its life science assets to OriGene Technologies for $16 million. The deal is expected to be finalized this quarter. SDIX's knowledge in antibody development and production "will complement OriGene's existing high-throughput monoclonal antibody capacity to develop the highest quality antibodies," OriGene Chairman and CEO Wei-Wu He said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL